Novel oral Type 1 diabetes drug gains US FDA IND designation
![](/46/pdcnewsitem/12/50/30/Heading%20image%20(19).png)
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment.
TIXiMED, a startup based at the University of Alabama at Birmingham, has received US FDA approval under an Investigational New Drug route for its novel oral Type 1 diabetes drug TIX100. The clearance will allow TIXiMED to begin human clinical trials. TIX100 was developed based on the work of Anath Shalev, MD, Nancy R and Eugene C Gwaltney Family Endowed Chair in Juvenile Diabetes Research at the university’s Divison of Endocrinology, Diabetes, and Metabolism and director of the institute’s Comprehensive Diabetes Center.
TIX100 gained IND approval after extensive safety pharmacology and toxicokinetic testing, with extensive development in chemistry, manufacturing, and control to ensure safety during clinical trials. The novel oral drug hopes to reduce the need for daily injections for patients. “Since TIX100 is available orally, it promises to ease the burden of the multiple daily insulin injections or insulin infusions people with Type 1 diabetes depend on,” commented Shalev. “We are so excited to see our work being translated into a better diabetes treatment that may impact so many people and provide a breakthrough for Type 1 diabetes.”
The mechanism of action for TIX100 revolves around TXNIP, a protein involved in oxidative stress and can cause beta cell death and dysfunction when elevated in pancreatic islets. Previous research conducted by Shalev demonstrated the importance of TXNIP in glucose toxicity and diabetic beta cell loss. Inhibiting TXNIP could protect these beta cells, promoting cell health and function. TIX100 effectively inhibits TXNIP, functioning differently from currently approved diabetes drugs. Additionally, non-specific TXNIP inhibition both prevented and reversed overt diabetes. The US FDA clearance will allow TIXiMED to further observe these effects in humans, following on from previous beneficial effects observed in mouse models of diabetes and selected humans with Type 1 diabetes.
TIXiMED grew out of the Bill L Harbert Institute for Innovation and Entrepreneurship. For her work in diabetes research and developing disease-changing therapies, as well as founding TIXiMED, Shalev was awarded the EntrepreHER Award in 2022. “It is extremely rewarding to see one of our startups reach such an important milestone,” commented T Michael Goodrich, president and executive board chair of TIXiMED and principal at First Avenue Ventures Life Science, Birmingham, Alabama. “I am confident that the continued success of TIXiMED will serve as a great example of what we can achieve when commercialising a university asset, both from a business perspective and in terms of positively impacting the local and global community.”
Source:
Type 1 diabetes: UAB startup gains FDA clearance to test novel oral drug [Accessed August 1, 2024] https://www.uab.edu/news/research/item/14275-type-1-diabetes-uab-startup-gains-fda-clearance-to-test-novel-oral-drug
Related News
-
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Alzheimer’s drug Leqembi rejected by EU drug regulator
The European Medicine’s Agency (EMA), the drug regulator for the EU, rejected Eisai and Biogen’s Alzheimer’s drug product Leqembi, citing the drug’s slowing of cognitive decline did not outweigh the risk of serious brain swellin... -
News Second obesity drug candidate from Roche shows early trial success
Following from its purchase of Carmot Therapeutics, Roche have announced positive early-stage trial success for its second obesity drug candidate acquired from Carmot Therapeutics. -
News Tumour microproteins could provide basis for cancer vaccines
A recent study published in Science Advances has identified a set of microproteins produced exclusively in liver tumours, which may provide a clear target for the development of a cancer vaccine. -
News Reworked once-daily weight-loss pill from Pfizer to progress
American pharmaceutical giant Pfizer have continued with a reworked version of their weight-loss pill danuglipron, progressing with a once-daily version of the pill. -
News CPHI Online Trend Report: what is pharmaceutical packaging really costing the industry?
The latest CPHI Online Trend Report dives into what it really costs to develop, manufacture, and deploy pharmaceutical packaging that balances sustainability concerns, patient safety, and drug efficacy. -
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance